Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice

Lindsay A. Becker(Stanford Medicine), Brenda Huang(Stanford University), Gregor Bieri(Stanford Medicine), K. Rosanna(Stanford University), David A. Knowles(Stanford University), Paymaan Jafar‐Nejad(Ionis Pharmaceuticals (United States)), James Messing(St. Jude Children's Research Hospital), Hong Joo Kim(St. Jude Children's Research Hospital), Armand Soriano(Ionis Pharmaceuticals (United States)), Georg Auburger(Goethe University Frankfurt), Stefan M. Pulst(Goethe University Frankfurt), J. Paul Taylor(St. Jude Children's Research Hospital), Frank Rigo(Ionis Pharmaceuticals (United States)), Aaron D. Gitler(Stanford University)
Nature
April 11, 2017
10.1038/nature22038
Cited by 580

Abstract

Related Papers

Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Manuela Neumann, Deepak M. Sampathu, Linda K. Kwong et al.|Science|2006|6.6k
Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis
Shuo‐Chien Ling, Magdalini Polymenidou, Don W. Cleveland|Neuron|2013|1.8k
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
Andrew C. Elden, Hyung Jun Kim, Michael P. Hart et al.|Nature|2010|1.3k
TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity
Brian S. Johnson, David Snead, Jonathan J. Lee et al.|Journal of Biological Chemistry|2009|801
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly Kordasiewicz, Lisa M. Stanek, Edward V. Wancewicz et al.|Neuron|2012|765